Back

Therapeutic Eradication of Cancer-associated Fibroblasts Inhibits in vivo progression of Pancreatic Cancer

Roos-Mattila, M.; Mustonen, H.; Vaha-Koskela, M.; Boyd, S.; Vainionpaa, S.; Hwang, R. F.; Puolakkainen, P.; Le Joncour, V.; Laakkonen, P.; Seppanen, H.

2025-11-05 cancer biology
10.1101/2025.11.04.686484 bioRxiv
Show abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with an unmet medical need. therapeutic elimination of cancer associated fibroblasts (CAFs), key drivers of tumor aggressiveness, has been the focus of recent studies. However, the inherent heterogeneity and plasticity of CAFs have hampered the development of CAF-targeted therapies. Clemastine, an FDA-approved cationic amphiphilic drug, is known to elicit cytotoxic lysosomal membrane permeabilization in solid tumors. We evaluated its efficacy in patient derived PDAC organoids and patient avatars. In vitro, half of the organoids responded to clemastine, although sensitivity did not predict in vivo outcomes. In vivo, clemastine treatment led to CAF depletion, halted cancer progression and delayed disease progression. To assess potential synergy with standard-of-care therapy, clemastine was combined with gemcitabine. The combination enabled dual targeting--clemastine effectively eliminated all CAF subtypes, while gemcitabine eradicated cancer cells - leading to inhibition of metastatic dissemination. These findings support clemastine as a promising companion therapy in PDAC, targeting the tumor-supportive microenvironment.

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 24%
6.7%
Similar papers in this journal
2
Cancer Research
● 130 papers in training set
Top 0.4%
6.7%
Similar papers in this journal
3
Cancer Discovery
● 66 papers in training set
Top 0.5%
5.4%
Similar papers in this journal
4
Gastroenterology
○ 42 papers in training set
Top 0.1%
5.4%
Similar papers in this journal
5
Cell Death & Disease
147 papers in training set
Top 0.5%
4.8%
6
Cancers
○ 213 papers in training set
Top 2%
3.2%
7
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.3%
3.2%
8
Gut
● 40 papers in training set
Top 0.3%
2.6%
9
Cancer Letters
○ 35 papers in training set
Top 0.4%
2.4%
10
Cell Death & Differentiation
○ 48 papers in training set
Top 0.4%
2.4%
11
Science Advances
● 1243 papers in training set
Top 15%
2.4%
12
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.4%
2.1%
13
JCI Insight
● 277 papers in training set
Top 4%
2.1%
14
eLife
● 5828 papers in training set
Top 51%
1.7%
50% of probability mass above
15
Journal of Clinical Investigation
● 179 papers in training set
Top 3%
1.7%
16
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.3%
1.7%
17
Cell Reports Medicine
○ 153 papers in training set
Top 2%
1.7%
18
Translational Oncology
○ 21 papers in training set
Top 0.4%
1.7%
19
Molecular Oncology
○ 55 papers in training set
Top 0.8%
1.5%
20
Molecular Cancer
○ 16 papers in training set
Top 0.1%
1.5%
21
Communications Biology
○ 993 papers in training set
Top 17%
1.5%
22
Scientific Reports
○ 3612 papers in training set
Top 58%
1.4%
23
Oncogene
○ 85 papers in training set
Top 1%
1.3%
24
British Journal of Cancer
○ 49 papers in training set
Top 0.9%
1.3%
25
Cell Reports
○ 1498 papers in training set
Top 22%
1.3%
26
Cellular and Molecular Gastroenterology and Hepatology
○ 46 papers in training set
Top 0.7%
1.1%
27
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1%
1.1%
28
Gastro Hep Advances
○ 11 papers in training set
Top 0.2%
1.1%
29
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.4%
1.1%
30
Cell Death Discovery
○ 58 papers in training set
Top 0.9%
1.1%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.